A citation-based method for searching scientific literature

Vinaya Gogineni, Susan Morand, Hannah Staats, Rachel Royfman, Monika Devanaboyina, Katelyn Einloth, Danielle Dever, Laura Stanbery, Phylicia Aaron, Luisa Manning, Adam Walter, Gerald Edelman, Lance Dworkin, John Nemunaitis. J Cancer 2021
Times Cited: 4







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The folate receptor as a rational therapeutic target for personalized cancer treatment.
Yehuda G Assaraf, Christopher P Leamon, Joseph A Reddy. Drug Resist Updat 2014
174
50

Association between tumor mutation burden and immune infiltration in ovarian cancer.
Suzhen Fan, Xiang Gao, Qiaohong Qin, Hongyu Li, Zhongfu Yuan, Shujun Zhao. Int Immunopharmacol 2020
5
50

Treatment of epithelial ovarian cancer.
Lindsay Kuroki, Saketh R Guntupalli. BMJ 2020
27
50

PARP inhibitors in ovarian cancer: An overview of the practice-changing trials.
Tiffany Foo, Angela George, Susana Banerjee. Genes Chromosomes Cancer 2021
10
50

Overexpression of folate binding protein in ovarian cancers.
G Toffoli, C Cernigoi, A Russo, A Gallo, M Bagnoli, M Boiocchi. Int J Cancer 1997
335
25

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Eileen E Parkes, Steven M Walker, Laura E Taggart, Nuala McCabe, Laura A Knight, Richard Wilkinson, Karen D McCloskey, Niamh E Buckley, Kienan I Savage, Manuel Salto-Tellez,[...]. J Natl Cancer Inst 2016
178
25

Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer.
Brandon M Roane, Rebecca C Arend, Michael J Birrer. Cancers (Basel) 2019
19
25

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A Wilson, Nicolai J Birkbak, Crispin T Hiley,[...]. Science 2016
25

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
141
25

Genomic correlates of response to immune checkpoint blockade.
Tanya E Keenan, Kelly P Burke, Eliezer M Van Allen. Nat Med 2019
157
25

Human tumor antigens for cancer vaccine development.
R F Wang, S A Rosenberg. Immunol Rev 1999
233
25

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
Inge S van Houdt, Berbel J R Sluijter, Laura M Moesbergen, Wim M Vos, Tanja D de Gruijl, Barbara G Molenkamp, Alfons J M van den Eertwegh, Erik Hooijberg, Paul A M van Leeuwen, Chris J L M Meijer,[...]. Int J Cancer 2008
89
25

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.
Paul Sabbatini, Philipp Harter, Giovanni Scambia, Jalid Sehouli, Werner Meier, Pauline Wimberger, Klaus H Baumann, Christian Kurzeder, Barbara Schmalfeldt, David Cibula,[...]. J Clin Oncol 2013
83
25

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
458
25

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.
Johnathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley,[...]. Gynecol Oncol Rep 2020
6
25

Hypermutated Tumors and Immune Checkpoint Inhibition.
Kristen K Ciombor, Richard M Goldberg. Drugs 2018
13
25

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
165
25

Role of DNA repair defects in predicting immunotherapy response.
Jing Zhang, David J H Shih, Shiaw-Yih Lin. Biomark Res 2020
11
25


Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
Neil Senzer, Minal Barve, Joseph Kuhn, Anton Melnyk, Peter Beitsch, Martin Lazar, Samuel Lifshitz, Mitchell Magee, Jonathan Oh, Susan W Mill,[...]. Mol Ther 2012
106
25

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.
Donastas Sakellariou-Thompson, Marie-Andrée Forget, Emily Hinchcliff, Joseph Celestino, Patrick Hwu, Amir A Jazaeri, Cara Haymaker, Chantale Bernatchez. Cancer Immunol Immunother 2019
6
25

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
H Arias-Pulido, A Cimino-Mathews, N Chaher, C Qualls, N Joste, C Colpaert, J D Marotti, M Foisey, E R Prossnitz, L A Emens,[...]. Breast Cancer Res Treat 2018
36
25

TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Khalil Choucair, Susan Morand, Laura Stanbery, Gerald Edelman, Lance Dworkin, John Nemunaitis. Cancer Gene Ther 2020
17
25

The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon. Nat Rev Cancer 2012
25

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Ignace Vergote, Deborah Armstrong, Giovanni Scambia, Michael Teneriello, Jalid Sehouli, Charles Schweizer, Susan C Weil, Aristotelis Bamias, Keiichi Fujiwara, Kazunori Ochiai,[...]. J Clin Oncol 2016
61
25

Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Sebastian Kreiter, Mathias Vormehr, Niels van de Roemer, Mustafa Diken, Martin Löwer, Jan Diekmann, Sebastian Boegel, Barbara Schrörs, Fulvia Vascotto, John C Castle,[...]. Nature 2015
599
25

Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer.
Bonnie Hylander, Elizabeth Repasky, Protul Shrikant, Marilyn Intengan, Amy Beck, Deborah Driscoll, Pankaj Singhal, Shashikant Lele, Kunle Odunsi. Gynecol Oncol 2006
63
25

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review.
B Pellegrino, A Musolino, A Llop-Guevara, V Serra, P De Silva, Z Hlavata, D Sangiolo, K Willard-Gallo, C Solinas. Transl Oncol 2020
18
25

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
25


Ovarian Cancer Immunotherapy: Turning up the Heat.
Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, Giorgio Valabrega. Int J Mol Sci 2019
57
25

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, Emiliano Calvo, Paolo A Ascierto, Akin Atmaca, Naiyer A Rizvi, Fred R Hirsch, Giovanni Selvaggi, Joseph D Szustakowski,[...]. Cancer Cell 2018
393
25


Recurrent epithelial ovarian cancer: an update on treatment.
Olivia W Foley, J Alejandro Rauh-Hain, Marcela G del Carmen. Oncology (Williston Park) 2013
78
25

Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.
S D Weitman, R H Lark, L R Coney, D W Fort, V Frasca, V R Zurawski, B A Kamen. Cancer Res 1992
794
25

BRCA mutation in high grade epithelial ovarian cancers.
Tarinee Manchana, Natacha Phoolcharoen, Patou Tantbirojn. Gynecol Oncol Rep 2019
15
25

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman,[...]. N Engl J Med 2015
25

Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage.
Gillian Dunphy, Sinéad M Flannery, Jessica F Almine, Dympna J Connolly, Christina Paulus, Kasper L Jønsson, Martin R Jakobsen, Michael M Nevels, Andrew G Bowie, Leonie Unterholzner. Mol Cell 2018
156
25

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
Marie Christine Wulff Westergaard, Rikke Andersen, Chloé Chong, Julie Westerlin Kjeldsen, Magnus Pedersen, Christina Friese, Thomas Hasselager, Henrik Lajer, George Coukos, Michal Bassani-Sternberg,[...]. Br J Cancer 2019
27
25

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
Renata Rodrigues da Cunha Colombo Bonadio, Rodrigo Nogueira Fogace, Vanessa Costa Miranda, Maria Del Pilar Estevez Diz. Clinics (Sao Paulo) 2018
28
25

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Elisabetta Gambale, Francesco Atzori, Federica Zoratto, Alessandro Parisi, Davide Brocco, Annagrazia Pireddu, Katia Cannita,[...]. Immunotherapy 2018
8
25

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, Emin Tahirovic, Ian S Hagemann, George Coukos. Gynecol Oncol 2012
354
25

The inhibitory effect of ellagic Acid on cell growth of ovarian carcinoma cells.
Yuan-Chiang Chung, Li-Cheng Lu, Ming-Hsiu Tsai, Yu-Jen Chen, Yi-Ying Chen, Shih-Ping Yao, Chih-Ping Hsu. Evid Based Complement Alternat Med 2013
37
25

Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.
Femke Hillen, Coen I M Baeten, Anouk van de Winkel, David Creytens, Daisy W J van der Schaft, Véronique Winnepenninckx, Arjan W Griffioen. Cancer Immunol Immunother 2008
90
25

The Human Genome Project: lessons from large-scale biology.
Francis S Collins, Michael Morgan, Aristides Patrinos. Science 2003
385
25

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
25

Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type.
Daniel J O'Shannessy, Elizabeth B Somers, Robert Smale, Yao-Shi Fu. Int J Gynecol Pathol 2013
54
25

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
25


Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
337
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.